{
  "docId": "019de075-e430-7299-a96e-811e562ad763",
  "docSlug": "dd1cc6bfd53a92cef2d40347c5bc25e6",
  "documentTitle": "Alkermes | Results Presentation Deck | 27 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 27,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 2,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-e430-7299-a96e-811e562ad763/14",
  "deckHref": "/decks/019de075-e430-7299-a96e-811e562ad763",
  "deckJsonHref": "/decks/019de075-e430-7299-a96e-811e562ad763.json",
  "deckAnchorHref": "/decks/019de075-e430-7299-a96e-811e562ad763#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.9,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "list",
      "text": "Designed to address underlying pathology of narcolepsy and achieve: Improved wakefulness duration and quality, Cataplexy control, Low therapeutic dose, Acceptable safety profile",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cacc517-8c19-4400-8fa6-0cd5109ac433",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.7
      },
      "kind": "list",
      "text": "Initial data from the ongoing Phase 1 study has shown: ALKS 2680 is generally well tolerated, Proof of concept in patients with narcolepsy type 1",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58574500-3700-457e-97e4-ea28ea5aa31f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "list",
      "text": "ALKS 2680 is a highly potent, orally bioavailable, selective OX2R agonist; ≥10 fold more potent than orexin A; >5,000-fold selectivity relative to OX1R",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9c84dc9b-d616-4d31-971a-7ec7e6642dc3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.6
      },
      "kind": "list",
      "text": "ALKS 2680 demonstrated dose-dependent improvements in wake duration and cataplexy control in a mouse model of narcolepsy",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8cdfc6c-2adb-48d8-b74e-a8a9cf00682e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "aData from preclinical studies using CHO cells. bOrexin DTA mice. CHO: Chinese Hamster Ovary; DTA: diphtheria toxin subunit A; OX1R: orexin receptor type 1; OX2R: orexin receptor type 2; PD: pharmacodynamic; PK: pharmacokinetic",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0732e26a-846e-4976-bcee-6a13e71c9f31",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "ALKS 2680 Is an Investigational Oral Orexin 2 Receptor Agonist for the Treatment of Narcolepsy",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0322cb3-dd41-4351-b76a-8b73359fcff2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "01ec3fc2-c8c6-4bbc-91b1-5b23030f8d37",
      "evidence": "list/bullet: Designed to address underlying pathology of narcolepsy and achieve: Improved wakefulness duration and quality, Cataplexy control, Low therapeutic dose, Acceptable safety profile",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 23,
      "from": 13,
      "beatId": "a2d3f125-9d63-41e7-ad4b-d97f1d4906af",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Market Size",
      "beatSlug": "sequoia-pitch-market-size",
      "evidence": "The preliminary results from a Phase 1 study of ALKS 2680 demonstrate potential for growth",
      "position": 2,
      "confidence": 0.7,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}